Drug intelligence / Profile preview

Nipah virus vaccine (Phylex BioSciences)

Development stage: Preclinical
Lead developer: Phylex BioSciences
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

Phylex BioSciences is developing an mRNA-based vaccine for the prevention of Nipah virus infection. The vaccine utilizes a proprietary platform where the messenger RNA encodes an antigen that is displayed on a self-assembling nanoparticle. This technology is designed to enhance the immune response by presenting the antigen in a multivalent, virus-like format. The candidate is currently in preclinical development, with the company pursuing parallel tracks for preclinical-grade and cGMP manufacturing.

Other names: Phylex Nipah mRNA vaccine

Targets

NiV (Nipah virus)

Beyond the preview

Go deeper on Nipah virus vaccine (Phylex BioSciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nipah virus vaccine (Phylex BioSciences).

Explore the full profile